WHO clears Takeda's dengue vaccine

The World Health Organization (WHO) has given its approval to Takeda Pharmaceuticals' dengue vaccine, a significant development in the fight against the mosquito-borne disease. This move opens the door for international procurement agencies to purchase the vaccine, which could potentially shield millions from the debilitating illness.

Historical Context of Dengue Fever

Dengue fever is a leading cause of severe illness and fatalities in over 120 Latin American and Asian countries. It is characterized by severe symptoms such as internal bleeding, organ failure, and even death. The disease lacks a specific treatment, and its prevalence has been on the rise globally due to climate change and the expanding range of mosquitoes that transmit it. In recent years, there has been a surge in outbreaks across the Americas, with a reported 206% increase in suspected dengue cases in the region compared to the same period in 2023.

Global Impact of Dengue

Dengue affects tens of millions of people each year. In most cases, it presents as mild symptoms, but severe infections can result in dengue hemorrhagic fever, which is a significant public health concern. The disease is transmitted by the Aedes aegypti mosquito, which is found in many parts of the world, including the Americas, Asia, and Africa. The WHO has reported a tenfold increase in dengue cases over the past generation, highlighting the need for effective vaccines and control measures.

Takeda's Qdenga Vaccine

Takeda's dengue vaccine, named Qdenga, has been approved by the WHO for use in children aged six to sixteen years living in areas with high dengue infection rates. The vaccine has shown approximately 84% efficacy in preventing hospitalization due to dengue and around 61% efficacy in averting disease symptoms. This level of efficacy is crucial in the fight against dengue, as it can significantly reduce hospitalization rates and alleviate the burden on healthcare systems.

Previous Challenges and Approvals

The development of a dengue vaccine has been challenging due to the nature of the disease. There are four serotypes of dengue, and infection with one does not protect against infection by another. In some cases, previous exposure to dengue can lead to more severe disease on subsequent infections. Despite these challenges, Takeda's vaccine has received approval in several countries, including the European Union, the United Kingdom, Brazil, Argentina, Indonesia, and Thailand. However, the company recently withdrew its application for the vaccine from the U.S. Food and Drug Administration (FDA), citing the need for additional data not captured by the clinical trial.

WHO Endorsement

The WHO's endorsement of Qdenga marks a significant milestone in the global effort to combat dengue. The WHO's director for the agency's approvals of medicines and vaccines, Rogerio Gaspar, hailed the decision as "an essential step in the expansion of global access to dengue vaccines." This endorsement allows international procurement agencies to purchase the vaccine, ensuring access to it in impoverished countries where dengue is a significant public health concern.

Clinical Trials and Efficacy

Clinical trials have demonstrated the effectiveness of Qdenga. The vaccine has shown significant efficacy in preventing hospitalization due to dengue and in reducing disease symptoms. These results are particularly important, as severe dengue cases can lead to serious complications and even death. The WHO's position paper on dengue vaccines highlights the need for vaccines that can protect against multiple serotypes and reduce the risk of severe disease.

Global Impact and Future Prospects

The WHO's approval of Qdenga has far-reaching implications for global health. The vaccine is expected to be distributed in areas with high dengue infection rates, particularly in Latin America and Asia. This move is particularly timely, given the recent surge in dengue cases in the Americas. The vaccine could potentially be used in public health emergencies, such as the current dengue epidemic in Rio de Janeiro, where authorities have initiated the rollout of the vaccine to vaccinate at least 3 million people.

Conclusion

The WHO's approval of Takeda's dengue vaccine is a significant step forward in the fight against this debilitating disease. The vaccine has shown promising efficacy in preventing hospitalization and reducing disease symptoms, making it a valuable tool in global disease control. As the vaccine becomes more widely available, it is expected to significantly reduce the burden of dengue on healthcare systems and improve public health outcomes in areas where the disease is prevalent. With the WHO's endorsement, international procurement agencies can now procure the vaccine, ensuring its availability in countries where it is most needed.

References

• WHO position paper on dengue vaccines – May 2024
• WHO clears Takeda's dengue vaccine amid surge in outbreaks
• Takeda withdraws application for dengue vaccine from FDA
• Preparedness for the Dengue Epidemic: Vaccine as a Viable Approach

---

This article is a testament to the ongoing efforts to combat dengue fever, a disease that continues to pose a significant threat to global health. The WHO's endorsement of Takeda's Qdenga vaccine is a crucial step in making this tool available to those who need it most.